Transition reminder: Vitamin B6; Artemisinin containing ingredients; Mollusc-derived ingredients 

Transition Reminder

Members are reminded that the end of the transition period for certain ingredient changes is approaching on 28 February 2023.

Some changes relate to pregnancy warnings, or allergen warnings, which are often subject to retail or consumer level recalls if the required statements are not included.

Vitamin B6

– maximum daily dose change from 200mg to 100 mg (adults);

– maximum daily dose change for children (depending on age group)

– warning statements on labels for products containing > 10 mg pyridoxine per MRDD.

Artemisinin containing herbs

– End of transition period to include a pregnancy warning for certain existing artemisinin containing ingredients.

Mollusc derived ingredients

– Updated allergen warning

These ingredients were subject to changes following the outcomes of the 2021-22 Permissible Ingredients Consultation. Please see CMA’s 27 September 2022 tech alert, the TGA Final Decisions Document and the TGA Oct 2022 publication on Vitamin B6 for more information. 

Please note: Due to recent changes in the Advertising Code ‘health warnings’, members should also ensure, as a priority, that relevant advertisements (e.g. where an advertisement facilitates directly the purchase or other supply of a medicine; and the medicine is not available for physical inspection by a consumer prior to purchase or other supply)  have the required warnings.

LinkedIn
Facebook
Twitter
Email

RECENT ARTICLES

Vale Stephen Myers

It is with great sadness that we learned of the passing of Emeritus Professor Stephen Myers late last week. Stephen was a giant in the

Read More